← Eichor
Condition: Sll Small Lymphocytic Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Sll Small Lymphocytic Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal
Phase 2 · 7 location(s) · City of Hope Medical Center · NCT07218510Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NA · 2 location(s) · Mayo Clinic · NCT05876923Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed o
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT05963217A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
Phase 2 · 31 location(s) · AbbVie · NCT02966756Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and
Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT05943496A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
Phase 1/Phase 2 · 9 location(s) · Jeanette Lundin · NCT04771507CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immuno
Phase 2 · 1 location(s) · University of Utah · NCT05183854A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymp
Phase 2 · 32 location(s) · Nurix Therapeutics, Inc. · NCT07221500Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
NA · 1 location(s) · Northwell Health · NCT05643235AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 4 location(s) · Newave Pharmaceutical Inc · NCT07342478Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Rec
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06967610Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small L
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07194980A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Phase 1/Phase 2 · 127 location(s) · BeOne Medicines · NCT05006716Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL o
Phase 1/Phase 2 · 24 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT05791409Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Phase 2 · 3 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT05694312Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00923507A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Phase 2 · 1 location(s) · Seema Bhat · NCT05417165Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg
Phase 1/Phase 2 · 29 location(s) · BeiGene · NCT05294731Long-term Follow-up Study of Patients Receiving CAR-T Cells
Phase N/A · 1 location(s) · Medical College of Wisconsin · NCT03375619Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · 152 location(s) · Alliance for Clinical Trials in Oncology · NCT07321652
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.